OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Infectious Diseases is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Ordinary people in extraordinary times	1858
Infectious disease surveillance update	1371
Chronicling PEPFAR's work in Africa	960
A step forward in the journey towards hookworm vaccines	783
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom	702
Adaora “Ada” Alise Adimora	610
Reflecting on lessons from the 2014–16 Ebola virus outbreak	606
Measles immunity gaps and outbreak risk in a shifting landscape	519
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	450
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	392
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	327
Correction to Lancet Infect Dis 2025; 25: e280–93	301
Threat of HIV and tuberculosis drug resistance after US funding cuts	301
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	293
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	266
The importance of understanding the infectious microenvironment	265
Shaping opportunities for future clinical trials in tuberculosis	258
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	255
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	248
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	247
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	244
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	240
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	238
Highlights from the sixth ESCMID Conference on Vaccines	228
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	223

Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	223
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	222
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	211
DNDi receives Dutch funding boost	210
HIV vaccine trial failure	208
Research in brief	197
Transitioning to endemicity with COVID-19 research	196
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	196
Attention to skin-related neglected tropical diseases	191
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	191
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines	182
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study	181
Bold measures to accelerate malaria elimination	178
Research in brief	177
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply	174
COVID-19 vaccination protects children and adolescents	173
The superiority of bivalent over monovalent booster vaccines	171
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	169
A patient with secondary syphilis following incomplete treatment of primary infection	167
Environment and infectious diseases	166
Updated criteria for paediatric sepsis and septic shock	166
Surge of cutaneous leishmaniasis in Pakistan	164
Infectious disease surveillance update	162
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children	161
Promoting diversity and equity in publishing	160
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	159
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	158
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	158
Listeria monocytogenes: a rare, deadly cause of peritonitis	155
The next chapter for Africa's genomic initiatives	151
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin	147
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	145
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	143
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	142
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	140
Mpox in people with past infection or a complete vaccination course: a global case series	138
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	137
Global cholera resurgence—a preventable tragedy	136
Research in brief	136
Research in brief	135
New flavours of tuberculosis treatment for children	135
Correction to Lancet Infect Dis 2025; 25: e47–58	134
Immune evasiveness of SARS-CoV-2 variants and vaccine selection	129
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	128
Theresa Ochoa—staying on top of infectious diseases in Peru	127
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	127
Infectious disease surveillance update	126
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study	126
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	126
Research in brief	125

COVID-19 mortality in Africa and Asia – Authors' reply	125
High-dose primaquine reduces vivax relapses: time for change	124
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	123
What can be learnt from the world's first national vaccination programme against gonorrhoea	123
RSV prevention: public health lessons from the southern hemisphere	121
Correction to Lancet Infect Dis 2025; 25: e622	121
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation	118
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	117
Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study	115
The global burden of cryptococcosis—a neglected tropical disease?	115
Correction to Lancet Infect Dis 2023; 23: e469	113
Super-spreaders: a historical review	111
Serpiginous-like choroiditis in ocular tuberculosis	110
The response of mpox-associated inflammatory syndrome to steroid therapy	109
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	107
History and evolution of tuberculosis and global health	107
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	106
Tuberculosis recovery in Georgia: implementing more by 24	104
Interplay of infection and vaccination in long-term protection from COVID-19	103
Election of Regional Director for the Western Pacific	103
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	103
WHO Pathogen X conference	102
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	102
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	102
Supporting healthcare access for refugees and migrants	102
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world	101
Emil Gotschlich	100
The implications of mpox breakthrough infections on future vaccination strategies	100
Curing chronic hepatitis B virus infection	100
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	98
WHO's first global infection prevention and control report	98
Is combination antiviral therapy for influenza the optimal approach?	96
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms	95
Sizing the reservoirs of malaria transmission: the contribution of school-aged children	95
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site	94
Severe influenza: is there a role for antiviral combinations?	92
Assessment of experimental malaria vaccine induced protection in pre-exposed populations	92
Full-dose NSAIDs at the first sign of respiratory infection?	91
Worrying lack of funding for tuberculosis	91
A new monoclonal in the arMAMentarium against malaria	90
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	90
Patient-centred approaches for drug-resistant tuberculosis	90
Elisabeth Presterl—always looking forward	89
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	88
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study	88
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study	87
Research in brief	87
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	86
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	84
Twin threats: climate change and zoonoses	84
Addressing the shortage of cholera vaccines	83
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	83
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update	82
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	82
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study	82
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	82
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	81
Post-viral sequelae of COVID-19 and influenza	80
Vaccine and surveillance implications of dengue underdetection	80
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	79
Infectious disease surveillance update	79
Spreading awareness on lymphatic filariasis	78
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	76
Clindamycin-resistant Streptococcus pyogenes in Chinese children	76
Correction to Lancet Infect Dis 2021; 21: 929–38	76
Lessons learnt from conducting a randomised clinical trial in eumycetoma	74
doxyPEP: a controversial new tool against STIs	74
COVID-19 mortality in Africa and Asia	74
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	74
DoxyPEP: thinking towards implementation	74
A step closer to elimination of meningococcal disease	73
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials	73
Pui-Ying Iroh Tam	72
A rare case of rabies-like Australian bat lyssavirus infection	72
Outbreaks compound Brazil's flooding disaster	71
Advancing integration: progress reported for skin NTDs	70
Research in brief	70
Moxidectin versus ivermectin for strongyloidiasis control	70
Social workers and neglected tropical diseases	70
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	69

The origin of SARS-CoV-2 variants of concern	69
Gender and geographical representation at infectious diseases and clinical microbiology conferences	69
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	69
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	68
Imprinted hybrid immunity against XBB reinfection	68
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	68
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	67
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	67
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	67
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	67
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	67
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	66
Child-friendly rifapentine formulation is a game changer	66
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	66
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	66
Is the end of gonorrhoea in sight?	65
Vaccine pragmatism in the 21st century	65
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	65
On the frontline during the COVID-19 pandemic	64
Correction to Lancet Infect Dis 2023; 23: e259–65	64
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	63
Sir Michael Anthony Epstein	63
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	63
Amal Saif Al-Maani—fighting antimicrobial resistance	62
Highlights from ECCMID 2022	62
Ivermectin for malaria control in mass drug administration programmes	62
The urgent need to scale-up fungal diagnostics in Africa	62
Sleeping sickness: time for dreaming	61
Human ocular thelaziosis—a zoonosis of the eye	61
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	61
Next-generation malaria subunit vaccines to reduce disease burden in African children	61
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	60
Re-emergence of Oropouche virus in Brazil and Latin America	60
Hong Kong's fifth COVID-19 wave—the worst yet	59
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	59
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	59
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	58
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	58
A tale of potential mpox reinfection	58
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	57
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	57
Understanding the immunogenicity of RTS,S in infants	56
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	56
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	56
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	56
A shared history	55
Alexandra King—promoting Indigenous self-determination	55
Correction to Lancet Infect Dis 2025; 25: e11–12	55
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data	54
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions	53
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	53
Deaths of unknown cause in DR Congo	53
Antiblackness in the Ebola response in Sierra Leone	53
COVID-19 versus influenza: the need to align policies with COVID-19 realities	53
Mpox control strategies: using behaviour change to complement, not replace, vaccination	52
Azithromycin mass drug administration: balancing survival benefits and risks in children	52
Global measles cases up 20% in 2023	52
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomi	51
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	51
Antibody durability at 1 year after Sputnik V vaccination	51
Correction to Lancet Infect Dis 2025; published online Feb 13. https://doi.org/10.1016/S1473-3099(24)00749-7	50
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African c	50
Revisiting oral antivirals for COVID-19 in the hospital setting	50
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry	50
A new key-player for onchocerciasis elimination	48
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths	48
Experts react to SAGO's preliminary report	48
A vanquished threat or a cautionary tale?	48
Artificial intelligence to transform public health in Africa	48
Developing the EAVE III platform for future health crises	47
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	47
Antibiotic stewardship in the real world	47
Learning and confirming in publicly funded antiviral trials	47
Successful use of interferon alfa-2a for persistent parvovirus B19 infection	47
Correction to Lancet Infect Dis 2023; 23: 789	47
A new formulation of praziquantel to achieve schistosomiasis elimination	47
Randomised controlled trials for mpox in endemic countries	47
Correction to Lancet Infect Dis 2022; published online Jan 25. https://doi.org/10.1016/S1473-3099(21)00586-7	46
Transmissibility of SARS-CoV-2 among fully vaccinated individuals	46
Monkeypox trial to begin in DR Congo	46
Humanitarian crisis in Tigray amidst civil war	46
Salmonella Typhimurium outbreak linked to chocolate	46
What is the pandemic potential of avian influenza A(H5N1)?	45
Infectious disease surveillance update	45
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	45
Lien Jih-ching	45
Candida albicans fungal ball in the eyeball	44
Lyda Osorio—tackling South America's infectious diseases	44
Correction to Lancet Infect Dis 2025; 25: 764–74	43
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	43
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prosp	43
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia	43
Struggling with a new dengue epidemic in Nepal	43
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	43
Correction to Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4	42